Prime Medicine elects Kelly and Schenkein to board, ratifies PwC as auditor

Prime Medicine, Inc.

Michael Kelly elected Class I director with 64.5M for, 1.3M withheld; David Schenkein with 62.0M for, 3.7M withheld.
Broker non-votes on director election totaled 1,517,331.
PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 with 67.3M for, 6.3K against, 11.5K abstentions.
Annual meeting held June 14, 2023; all proposals approved by stockholders.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Prime Medicine, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was ratified, based on the following votes:

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Prime Medicine, Inc. shareholders approved Election of Michael Kelly and David Schenkein as Class I Directors at the 2023-06-14 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

Each of the following nominees was elected as a Class I Director to serve until the Company’s 2026 annual meeting of stockholders, and until his respective successor shall have been duly elected and qualified, based on the following votes:

View on SEC.gov

Browse all shareholder votes →

Prime Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-022447

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.